Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Revenue (2016 - 2025)

Historic Revenue for Neurocrine Biosciences (NBIX) over the last 14 years, with Q4 2025 value amounting to $805.5 million.

  • Neurocrine Biosciences' Revenue rose 2832.56% to $805.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.9 billion, marking a year-over-year increase of 2144.95%. This contributed to the annual value of $2.9 billion for FY2025, which is 2144.95% up from last year.
  • As of Q4 2025, Neurocrine Biosciences' Revenue stood at $805.5 million, which was up 2832.56% from $794.9 million recorded in Q3 2025.
  • Neurocrine Biosciences' 5-year Revenue high stood at $805.5 million for Q4 2025, and its period low was $236.6 million during Q1 2021.
  • Moreover, its 4-year median value for Revenue was $515.3 million (2024), whereas its average is $528.3 million.
  • As far as peak fluctuations go, Neurocrine Biosciences' Revenue tumbled by 446.43% in 2021, and later surged by 3037.33% in 2024.
  • Neurocrine Biosciences' Revenue (Quarter) stood at $296.0 million in 2021, then soared by 74.05% to $515.2 million in 2023, then increased by 21.84% to $627.7 million in 2024, then grew by 28.33% to $805.5 million in 2025.
  • Its last three reported values are $805.5 million in Q4 2025, $794.9 million for Q3 2025, and $687.5 million during Q2 2025.